SCIENCE OF
POSSIBILITY
At Vertex, we invest in scientific innovation to create transformative medicines for people with serious diseases.
The U.S. FDA clears our Investigational New Drug application for the potential treatment of autosomal dominant polycystic kidney disease (ADPKD)
The European Commission (EC) approves our CRISPR-based treatment for sickle cell disease and transfusion-dependent beta thalassemia for the European Union
Vertex announces positive Phase 3 results for our investigational triple combination therapy for the treatment of cystic fibrosis
Vertex announces Q4 and full year 2023 financial results
We’ve announced positive Phase 3 results from our investigational, non-opioid treatment for moderate-to-severe acute pain
Working at Vertex
Working at Vertex
Our company is built on an inclusive culture that brings together the best and brightest in every field striving for one goal: to improve the lives of people with serious diseases.
Find a Vertex clinical trial
Volunteers who participate in clinical trials
help make new medicines a reality.
Featured Stories